Drugs / Terbogrel
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02222987 | Feb → Mar 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02223000 | Mar → Jul 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02223494 | Oct 1998 → Mar 2000 | pulmonary hypertension | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT02223481 | May 1998 → Sep 1999 | pulmonary hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02223013 Comparator | Apr → May 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Terbogrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02222987 ↗ |
| Known as | BIBV 308 SE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02223000 ↗ |
| Action | Inhibit | “Thromboxane A2 receptor antagonist” CHEMBL281398 ↗1“Thromboxane-A synthase inhibitor” CHEMBL281398 ↗ |
| Modality | Small molecule | — CHEMBL281398 ↗ |
| Route | Oral | “Administered Orally” NCT02223000 ↗ |
| Target | TBXA2R | “Thromboxane A2 receptor antagonist” CHEMBL281398 ↗ |
| Target | TBXAS1 | “Thromboxane-A synthase inhibitor” CHEMBL281398 ↗ |